Topic: multiple sclerosis
Late last month, a court refused to block copies of Acorda’s Ampyra. So the New York drugmaker took matters into its own hands.
Roche's first-half sales climbed 7% to $28.3 billion, their fastest clip in about three years, thanks to stepped-up performance from its newer drugs.
Biogen grew sales 9% in the second quarter, beating Street expectations, but analysts on the company's conference call were focused elsewhere.
In four suits filed before the Delaware District Court, Novartis is looking to block Gilenya generic entrance before 2027.
A patent ruling for Novartis will give Celgene time to secure FDA approval for its Gilenya rival and persuade physicians that it's a safer MS pill.
Mylan has slashed its list price on generic Copaxone, and the move has industry watchers scratching their heads.
England’s cost watchdogs aren’t going to pay for Roche's Ocrevus, the only approved PPMS therapy—that is, until it gets cheaper.
NICE is now endorsing Ocrevus for NHS coverage in relapsing-remitting MS and will deliver a decision on the primary progressive form soon.
Even if Acorda loses its upcoming appeal on Ampyra's patents, its sales force won’t have to worry, CEO Ron Cohen says.
A new study showed Ocrevus could reduce patients' immune responses to vaccines against tetanus, seasonal flu and pneumococcus.